Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) will release its second quarter 2022 financial and operational results after the market closes on August 4, 2022. A live conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join the call by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international). A replay will be available for at least 30 days on its Investors website. Voyager Therapeutics focuses on developing AAV gene therapy treatments for serious diseases with its proprietary TRACER™ capsid platform.

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate update.

The conference call may be accessed by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international) and asking for the Voyager Therapeutics earnings call. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay will be available at the same link after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Voyager’s TRACER™ capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com       LinkedIn       Twitter 

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

FAQ

When will Voyager Therapeutics report Q2 2022 financial results?

Voyager Therapeutics will report its Q2 2022 financial results on August 4, 2022.

What time is the Voyager Therapeutics conference call?

The conference call for Voyager Therapeutics will be held at 4:30 p.m. ET on August 4, 2022.

How can I listen to the Voyager Therapeutics earnings call?

You can listen to the earnings call by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international). A live webcast is also available on the Voyager Investors website.

Is there a replay available for the Voyager Therapeutics conference call?

Yes, a replay of the Voyager Therapeutics conference call will be available for at least 30 days following the call.

What is the focus of Voyager Therapeutics?

Voyager Therapeutics specializes in developing next-generation AAV gene therapies for serious diseases using its proprietary TRACER™ capsid discovery platform.